NENizar El-Murr

Nizar El-Murr

*This is an algorithmically generated author record based on publicly available information.

Nizar El-Murr has a total of 174 co-authors. Here are the top co-authors by number of shared publications:

  • Jean-François Fléjou

    INSERM, UMRS 938-Centre de Recherche Saint-Antoine, Equipe 'Instabilité des Microsatellites et Cancers', Equipe labellisée par la Ligue Nationale contre le Cancer, Paris, France Université Pierre et Marie Curie, Paris, France AP-HP, Hôpital Saint-Antoine, Service d'Anatomie et Cytologie Pathologiques, Paris, France

    3 shared publications
  • Magali Svrcek

    INSERM, UMRS 938-Centre de Recherche Saint-Antoine, Equipe 'Instabilité des Microsatellites et Cancers', Equipe labellisée par la Ligue Nationale contre le Cancer, Paris, France Université Pierre et Marie Curie, Paris, France AP-HP, Hôpital Saint-Antoine, Service d'Anatomie et Cytologie Pathologiques, Paris, France

    3 shared publications
  • Alex Duval

    INSERM, UMRS 938-Centre de Recherche Saint-Antoine, Equipe 'Instabilité des Microsatellites et Cancers', Equipe labellisée par la Ligue Nationale contre le Cancer, Paris, France Université Pierre et Marie Curie, Paris, France

    2 shared publications
  • Céline Nicolazzi

    Sanofi Oncology Research, Vitry-sur-Seine, France

    2 shared publications
  • Jacques Cosnes

    University Pierre et Marie Curie-Paris 6, Paris, France 4 Department of Gastroenterology, Saint-Antoine Hospital, AP-HP, Hôpitaux Universitaires Est Parisien, Paris, France

    2 shared publications
  • Kristell Wanherdrick

    INSERM, UMRS 938-Centre de Recherche Saint-Antoine, Equipe 'Instabilité des Microsatellites et Cancers', Equipe labellisée par la Ligue Nationale contre le Cancer, Paris, France Université Pierre et Marie Curie, Paris, France

    2 shared publications

Latest Publications

  • Étude de l'impact des microARNs sur la carcinogenèse des cancers colorectaux instables sur les séquences répétées microsatellites du génome

    by Nizar El-Murr

    La progression tumorale MSI (Microsatellite Instable) est un processus multi-étapes résultant de mutations générées par un processus d'instabilité génétique qui affecte en majorité les motifs répétés en tandem de l'ADN (microsatellites). Ces mutations contribuent à l'oncogenèse lorsqu'elles perturbent la fonction d'oncogènes ou de gènes suppresseurs de tumeurs. Le trait phénotypique MSI est consécutif à l'inactivation du système de réparation des mésappariements de l'ADN (système MMR). Dans ce travail, je me suis intéressé au rôle des microARNs dans l'oncogenèse MSI. Les microARNs régulent l'expression de nombreux gènes pouvant avoir un rôle clé dans le cancer. J'ai donc fait l'hypothèse d'un rôle de ces microARNs lors des différentes étapes du processus tumorigénique MSI. Tout d'abord nous avons mis en évidence une surexpression du miR-155 (ciblant les principales protéines MMR) au niveau de la muqueuse colique non transformée des malades atteints d'une Maladie Inflammatoire Chronique Intestinale, qui pourrait constituer un évènement pré-tumoral favorisant l'émergence de clones MMR-déficients (notion d'effet de champs). Dans une deuxième partie, nous avons pu identifier la première mutation somatique touchant un microARN. Il s'agit du miR-3613 dont la répétition microsatellite est entièrement localisée dans le miR mature. L'instabilité au niveau de ce miR conduit à des changements de séquence à l'extrémité 3' du miR (notion d'IsomiRs). Les isomiRs produits ont un répertoire de cibles qui pour certaines sont communes à la forme sauvage et pour d'autres spécifiques à chacun des variants.

  • SAR442085, a novel anti-CD38 antibody with enhanced antitumor activity against multiple myeloma

    by Sahar Kassem, Béré K. Diallo, Nizar El-Murr, Nadège Carrié, Alexandre Tang, Alain Fournier, Hélène Bonnevaux, Céline Nicolazzi, Marine Cuisinier, Isabelle Arnould, et al.

    Anti-CD38 monoclonal antibodies (mAbs) represent a breakthrough in the treatment of multiple myeloma (MM), yet some patients fail to respond or progress quickly with this therapy, highlighting the need for novel approaches. In this study we compared the preclinical efficacy of SAR442085, a next-generation anti-CD38 mAb with enhanced affinity for activating Fcγ receptors (FcγR), with first-generation anti-CD38 mAb daratumumab and isatuximab. In surface plasmon resonance and cellular binding assays, we found that SAR442085 had higher binding affinity than daratumumab and isatuximab for FcγRIIa (CD32a) and FcγRIIIa (CD16a). SAR442085 also exhibited better in vitro antibody-dependent cellular cytotoxicity (ADCC) against a panel of MM cells expressing variable CD38 receptor densities including MM patients’ primary plasma cells. The enhanced ADCC of SAR442085 was confirmed using NK-92 cells bearing low and high affinity FcγRIIIa (CD16a)-158F/V variants. Using MM patients’ primary bone marrow cells, we confirmed that SAR442085 had an increased ability to engage FcγRIIIa, resulting in higher natural killer (NK) cell activation and degranulation against primary plasma cells than preexisting Fc wild-type anti-CD38 mAbs. Finally, using huFcgR transgenic mice that express human Fcγ receptors under the control of their human regulatory elements, we demonstrated that SAR442085 had higher NK cell-dependent in vivo antitumor efficacy and better survival than daratumumab and isatuximab against EL4 thymoma or VK*MYC myeloma cells overexpressing human CD38. These results highlight the preclinical efficacy of SAR442085 and support the current evaluation of this next-generation anti-CD38 antibody in phase I clinical development in patients with relapsed/refractory MM.


  • Open Access

    Trispecific antibodies enhance the therapeutic efficacy of tumor-directed T cells through T cell receptor co-stimulation

    by Lan Wu, Edward Seung, Ling Xu, Ercole Rao, Dana M. Lord, Ronnie R. Wei, Virna Cortez-Retamozo, Beatriz Ospina, Valeriya Posternak, Gregory Ulinski, et al.

    Despite the significant therapeutic advances provided by immune-checkpoint blockade and chimeric antigen receptor T cell treatments, many malignancies remain unresponsive to immunotherapy. Bispecific antibodies targeting tumor antigens and activating T cell receptor signaling have shown some clinical efficacy; however, providing co-stimulatory signals may improve T cell responses against tumors. Here, we developed a trispecific antibody that interacts with CD38, CD3 and CD28 to enhance both T cell activation and tumor targeting. The engagement of both CD3 and CD28 affords efficient T cell stimulation, whereas the anti-CD38 domain directs T cells to myeloma cells, as well as to certain lymphomas and leukemias. In vivo administration of this antibody suppressed myeloma growth in a humanized mouse model and also stimulated memory/effector T cell proliferation and reduced regulatory T cells in non-human primates at well-tolerated doses. Collectively, trispecific antibodies represent a promising platform for cancer immunotherapy.


  • A Vulnerability of a Subset of Colon Cancers with Potential Clinical Utility

    by Loredana Vecchione, Valentina Gambino, Jonne Raaijmakers, Andreas Schlicker, Arianna Fumagalli, Mariangela Russo, Alberto Villanueva, Evelyne Beerling, Alice Bartolini, David G. Mollevi, et al.


  • HSP110 T17 simplifies and improves the microsatellite instability testing in patients with colorectal cancer

    by Olivier Buhard, Anaïs Lagrange, Agathe Guilloux, Chrystelle Colas, Mouna Chouchène, Kristell Wanherdrick, Florence Coulet, Erell Guillerm, Coralie Dorard, Laetitia Marisa, et al.

    Background Every colorectal cancer (CRC) patient should be tested for microsatellite instability (MSI, a marker for defective DNA mismatch repair) as a first screen for Lynch syndrome (LS). In this study, we investigated whether it may be possible to improve the detection of MSI in CRC. We examined whether the HT17 DNA repeat (critical for correct splicing of the chaperone HSP110) might constitute a superior marker for diagnosis of the MSI phenotype in patients with CRC compared with the standard panel of markers (pentaplex). Methods The HT17 polymorphism was analysed in germline DNA from 1037 multi-ethnic individuals. We assessed its sensitivity and specificity for detecting MSI in a multicentre, population-based cohort of 685 patients with CRC and an additional series of 70 patients with CRC considered to be at-risk of LS. All cases were screened earlier for MSI using pentaplex markers. Cases showing discordant HT17/pentaplex results were further examined for the expression of mismatch repair proteins. Results HT17 status was analysed independently and blinded to previous results from pentaplex genotyping. HT17 showed no germline allelic variation outside a very narrow range. Compared with the pentaplex panel, HT17 showed better sensitivity (0.984 (95% CI 0.968 to 0.995) vs 0.951 (95% CI 0.925 to 0.972)) and similar specificity (0.997 (95% CI 0.989 to 1.000) for both) for the detection of MSI. Furthermore, HT17 alone correctly classified samples judged to be uncertain with the pentaplex panel and showed excellent ability to detect MSI in patients with LS. Conclusions HT17 simplifies and improves the current standard molecular methods for detecting MSI in CRC.


  • Open Access

    Small Bowel Adenocarcinomas Complicating Crohnʼs Disease Are Associated With Dysplasia

    by Magali Svrcek, Gael Piton, Jacques Cosnes, Laurent Beaugerie, Severine Vermeire, Karel Geboes, Antoinette Lemoine, Pascale Cervera, Nizar El-Murr, Sylvie Dumont, et al.

    Background. Crohn's disease (CD) is associated with an increased risk of small bowel adenocarcinoma (SBA). However, there are no guidelines for the screening an


  • NRAS Mutation Is the Sole Recurrent Somatic Mutation in Large Congenital Melanocytic Nevi

    by Christelle Charbel, Romain H. Fontaine, Gabriel G. Malouf, Arnaud Picard, Natacha Kadlub, Nizar El-Murr, Alexandre How-Kit, Xiaoping Su, Aurore Coulomb-L'Hermine, Jorg Tost, et al.


  • Cap polyposis and colitis cystica profunda: a rare association

    by Riad Arana, Jean‐François Fléjou, Yann Parc, Nizar El‐Murr, Jacques Cosnes, Magali Svrcek


  • Overexpression of microRNAs-155 and 21 targeting mismatch repair proteins in inflammatory bowel diseases

    by M. Svrcek, N. El-Murr, K. Wanherdrick, S. Dumont, L. Beaugerie, J. Cosnes, J.-F. Colombel, E. Tiret, J.-F. Flejou, T. Lesuffleur, et al.

    Microsatellite instability (MSI) due to mismatch repair (MMR) deficiency is reported in 5-10% of colorectal cancers (CRCs) complicating inflammatory bowel diseases (IBD). The molecular mechanisms underlying MMR deficiency may be different in IBD CRCs, and in sporadic and hereditary MSI tumors. Here, we hypothesize that overexpression of miR-155 and miR-21, two inflammation-related microRNAs that target core MMR proteins, may constitute a pre-neoplastic event for the development of MSI IBD CRCs. We studied miR-155 and miR-21 expression using real-time quantitative PCR in MSI (n = 10) and microsatellite stable (n = 10) IBD CRCs, and in MSI (n = 32) and microsatellite stable (n = 30) non-IBD CRCs. We also screened colonic samples from IBD patients without cancer (n = 18) and used healthy colonic mucosa as controls (n = 20). MiR-155 and miR-21 appeared significantly overexpressed not only in the colonic mucosa of IBD subjects without CRC but also in neoplastic tissues of IBD patients compared with non-IBD controls (P < 0.001). Importantly, in patients with IBD CRCs, miR-155 and miR-21 overexpression extended to the distant non-neoplastic mucosa (P < 0.001). Ratios of expressions in tumors versus matched distant mucosa revealed a nearly significant association between miR-155 overexpression and MSI in IBDs (P = 0.057). These results show a strong deregulation of both MMR-targeting microRNAs in IBD subjects with or without cancer. MiR-155 overexpression being particularly associated to MSI IBD CRCs and extending to distant non-neoplastic mucosa, strongly suggests that a pre-neoplastic miR-155 field defect may promote MSI-driven transformation of the colonic mucosa. The detection and monitoring of miR-155 field defect may, therefore, have implications for the prevention and treatment of MSI IBD CRCs.


  • Behavior of a hammerhead ribozyme in aqueous solution at medium to high temperatures

    by Nizar El-Murr, Marie-Christine Maurel, Martina Rihova, Jacques Vergne, Guy Hervé, Mikio Kato, Kunio Kawamura

    The “RNA world” hypothesis proposes that—early in the evolution of life—RNA molecules played important roles both in information storage and in enzymatic functions. However, this hypothesis seems to be inconsistent with the concept that life may have emerged under hydrothermal conditions since RNA molecules are considered to be labile under such extreme conditions. Presently, the possibility that the last common ancestor of the present organisms was a hyperthermophilic organism which is important to support the hypothesis of the hydrothermal origin of life has been subject of strong discussions. Consequently, it is of importance to study the behavior of RNA molecules under hydrothermal conditions from the viewpoints of stability, catalytic functions, and storage of genetic information of RNA molecules and determination of the upper limit of temperature where life could have emerged. In the present work, self-cleavage of a natural hammerhead ribozyme was examined at temperatures 10–200 °C. Self-cleavage was investigated in the presence of Mg2+, which facilitates and accelerates this reaction. Self-cleavage of the hammerhead ribozyme was clearly observed at temperatures up to 60 °C, but at higher temperatures self-cleavage occurs together with hydrolysis and with increasing temperature hydrolysis becomes dominant. The influence of the amount of Mg2+ on the reaction rate was also investigated. In addition, we discovered that the reaction proceeds in the presence of high concentrations of monovalent cations (Na+ or K+), although very slowly. Furthermore, at high temperatures (above 60 °C), monovalent cations protect the ribozyme against degradation.